REPEAT REVASCULARIZATION AFTER BARE-METAL VS DRUG-ELUTING STENTS

doi:N/A

eISSN: 1994-4624 / ISSN: 1813-176x

International Journal of Molecular Medicine and Advance Sciences

2021, Volume 17, Issue 2 : 22-25

Commentary Article

REPEAT REVASCULARIZATION AFTER BARE-METAL VS DRUG-ELUTING STENTS

Sameer A. Siddiqui

Priyanka Bose

Mauro Santini

Department of Interventional Cardiology, Royal Heart Institute, Mumbai, India

Center for Statistical Medicine, Singapore National Health University, Singapore

European Institute of Cardiac Sciences, Milan, Italy

Received

Aug. 18, 2021

Revised

Sept. 29, 2021

Accepted

Nov. 11, 2021

Published

Dec. 21, 2021

Abstract

Bare-metal stents (BMS) historically served as the primary intervention for percutaneous coronary interventions (PCI). However, their high rates of in-stent restenosis (ISR) led to increased repeat revascularization procedures. Drug-eluting stents (DES) were introduced to reduce neointimal hyperplasia, but long-term comparative evidence, especially in multi-ethnic cohorts, remains limited. This retrospective cohort study examines 1,560 patients over a 7-year period to compare repeat revascularization between BMS and DES. Results indicate significantly lower target lesion revascularization (TLR) in DES (12.8%) versus BMS (38.4%) (p < 0.001). Poor glycemic control, smoking history, and multi-vessel disease were key predictors of repeat intervention. DES provide superior long-term clinical benefit and should remain first-line for PCI unless contraindicated.

Keywords

Restenosis

PCI

Drug-eluting stent

Bare-metal stent

Target lesion revascularization

Coronary artery disease

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.

Int. J. Mol. Med. Adv. Sci. open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.

Recommended Articles

Personalized Healthcare Using Genomic Data: Advancing Precision Medicine Through Genomic Innovation

Elizabeth R. Morgan,

Arjun K. Sharma,

Sophia L. Bennett,

Ahmed F. Rahman

51-55

Mental Health Awareness and Help-Seeking Behavior: A Comprehensive Study of Knowledge, Attitudes, Barriers, and Interventions

Olivia M. Richardson,

James K. Patel,

Aisha N. Rahman,

Michael T. Bennett